Halofuginone Oral Antiviral for SARS-CoV-2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent clinical need for antiviral therapeutics that can prevent and inhibit COVID-19-associated morbidity and mortality, particularly those that can be administered early after symptom onset to prevent the development of severe respiratory disease, as existing treatments like Remdesivir have modest benefits and are limited by requiring intravenous administration.
Innovation Solution
Halofuginone or its pharmaceutically acceptable salts, particularly the 2R,3S-(+) enantiomer, are administered to inhibit SARS-CoV-2 attachment and replication by targeting the prolyl-tRNA synthetase pathway, reducing heparan sulfate biosynthesis, and activating the integrated stress response, thereby preventing viral attachment and propagation in human lung airway epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Remdesivir is administered intravenously to treat severe COVID-19, then it can provide therapeutic benefit to hospitalized patients, but it cannot be used in pre-symptomatic or early symptomatic mild disease
Solution Approach 1:
The patent replaces the intravenous administration route with an oral administration route by using halofuginone, a small molecule compound that can be absorbed through the gastrointestinal tract. This substitution eliminates the need for invasive procedures while maintaining therapeutic effectiveness, allowing treatment to begin earlier in the disease course.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of the treatment by using a compound with different absorption, distribution, metabolism, and excretion characteristics. Halofuginone's oral bioavailability and tissue penetration properties enable it to achieve effective concentrations in lung tissue through the gastrointestinal route, unlike Remdesivir which requires direct intravenous delivery.
2Reliability
If Remdesivir is administered early to prevent severe disease, then it may provide greater benefit, but clinical trials show it provides only modest clinical benefit
Solution Approach 1:
The patent uses halofuginone as an intermediary compound that targets a different mechanism in the viral replication pathway. By inhibiting prolyl-tRNA synthetase and blocking heparan sulfate biosynthesis, halofuginone prevents viral attachment and entry into host cells, providing a complementary or alternative mechanism to Remdesivir's RNA polymerase inhibition.
Solution Approach 2:
The patent emphasizes preliminary action by administering halofuginone before viral infection or at the very early stages of infection to prevent viral attachment. By targeting heparan sulfate biosynthesis in advance, the compound creates a protective effect that prevents the virus from establishing infection, rather than attempting to treat established severe disease.
3Reliability
If small molecules are designed to manipulate cellular heparan sulfate biosynthesis, then SARS-CoV-2 attachment can be blocked, but the complexity of discovering and optimizing such molecules increases
Solution Approach 1:
The patent demonstrates that halofuginone, originally developed for anti-fibrotic and anti-cancer indications, has been repurposed as an antiviral agent. This multi-functionality reduces drug discovery complexity by leveraging existing compounds with known safety profiles and pharmacokinetic properties, rather than de novo design of heparan sulfate biosynthesis inhibitors.
Solution Approach 2:
The patent uses halofuginone, a compound with an established chemical structure and manufacturing process, rather than creating entirely new small molecules. This approach copies the successful pharmacological properties of an existing drug to achieve the desired antiviral effect, simplifying the discovery and development process compared to designing novel heparan sulfate pathway inhibitors from scratch.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Halofuginone effectively inhibits SARS-CoV-2 spike protein binding, reduces viral replication, and prevents infection in various cell types, including primary human bronchial epithelial cells, with a potent antiviral effect demonstrated in both in vitro and in vivo models, offering a promising treatment for COVID-19 that can be administered orally.
Implementation Method 1
reducing heparan sulfate biosynthesis
Implementation Method 2
targeting the prolyl-tRNA synthetase pathway
Implementation Method 3
activating the integrated stress response
Data Source
AI summary
The present disclosure relates to treatment or prevention of a disease, such as COVID-19, in a subject by administering to the subject a therapeutically effective amount of halofuginone or a derivative or pharmaceutically acceptable salt thereof.